

Newpiravir 200

Molnupiravir Capsules

Rx only medicine

**200 mg
40 Caps.**



GCAP

Composition:
Each hard gelatin capsule contains:
Molnupiravir 200 mg
Excipients q.s.

Colour: Approved Colour used in empty capsule shell.

Dosage: As directed by the Physician.

Storage: Store below 25°C. Protect from light.

Keep all medicines out of reach of children.

Keep the container tightly closed after use.

CAUTION: Not to be sold by retail without the prescription of a Registered Medical Practitioner.

MOLNUPIRAVIR Information Packet

GCAP Group alliance members work together to promote the well-being of humanity throughout the world.

Our core mission is to advance new frontiers of science, tech innovation, and policymaking to solve global challenges.

In the spirit of humanitarianism, reverence for life and a high sense of social responsibility we are offering the game changing U.S. FDA approved anti-viral, Molnupiravir.



GCAP GROUP
GLOBAL COVID ALLIANCE PARTNERS

The Foundation of our Commitment.

1



Called a game changer, Merck's antiviral, Molnupiravir received U.S. Federal Drug Administration (FDA) approval in December, 2021. This life saving, easy to administer, oral treatment medication sells to first world nations for US \$700 per bottle. Each bottle contains one course, or a qty of 40, 200mg tablets. Reduces hospitalization and death by 30-to-50% in high-risk, unvaccinated individuals.

To learn more, click on the below

[U.S. FDA.gov](https://www.fda.gov)

[Emergency Use Authorization Approval](#)
[Direct letter to Merck](#)


[Merck.com](https://www.merck.com)

[Merck Receives U.S. FDA Emergency Use Authorization for COVID-19 Treatment](#)

[U.S. FDA.gov](https://www.fda.gov)

[Frequently Asked Questions](#)
[Emergency Use Authorization Molnupiravir](#)

2



With the understanding that developing nations need access to affordable life saving medications, Merck signed an agreement with the Medicines Patent Pool (MPP). This non-profit is a United Nations backed, public health organization working to ensure low-and-middle income nations have access to life-saving medications such as Molnupiravir to address the current COVID health crisis.

To learn more, click on the below

[World Health Organization](https://www.who.int)

[Molnupiravir Licensing agreement](#)
[Medicines Patent Pool](#)

[Medicines Patent Pool \(MPP\)](#)

[Signed Agreement](#)
[Merck and MPP](#)

[Medicines Patent Pool](#)

[Who We Are](#)
[About Us](#)

3



India is the largest provider of generic medicines globally. While its prices are low, strict guidelines and rules enforced by India's Central Drugs Standard Control Organization ensure quality exports produced to high international standards. MPP has recognized India's pharmaceutical manufacturing strengths and is collaborating with CDSCO to manufacture quality generic Molnupiravir from qualified Indian manufactures.

To learn more, click on the below

[Indian Pharmaceutical](#)

[Industry 2021](#)
[The Future is Now](#)

[McKinsey & Company](#)

[India Pharma 2020](#)
[Realising True Potential](#)

[Washington Post](#)

[India's Low Pharma Costs Good for drug companies and good for consumers](#)

The Foundation of our Commitment.

4




सत्यमेव जयते
Government Of India

The Medicines Patent Pool license has granted the Government of India and in turn, India's Central Drugs Standard Control Organization (CDSCO) the right to authorize Indian based pharmaceutical manufacturers who meet India's strict standards and the World Health Organization's General Manufacturing Guidelines to manufacture Molnupiravir for export to the global market.



5



Molnupiravir

Molnupiravir interferes with the viruses ability to replicate, keeping virus levels low in the body. This reduces the severity of COVID. In clinical trials, Molnupiravir has shown to reduce hospitalizations and death by 30% to 50% when given to high risk, unvaccinated volunteers within 5 days of showing symptoms. It's frequently called, a game changer in treating COVID.

To learn more, click on the below

[U.S. FDA.gov](https://www.fda.gov)

[Merck Presentation](#)

[US Food & Drug Admin Advisory Committee](#)

[New England Journal Of Medicine](#)

[Molnupiravir for Oral Treatment in Nonhospitalized Patients](#)

[FDA.Gov](#)

[Fact Sheet for Healthcare Providers: EUA for Molnupiravir](#)

6



When taken the first 5 days of infection, it keeps virus levels low in the body and reduces the severity of the disease.

Molnupiravir is meant for people with risk factors such as obesity, aged 60+, heart disease, diabetes or cancer.

Designed to treat mild-to-moderate COVID-19 cases.

To learn more, click on the below

[Yale Medicine](#)

[9 Things You Need to Know About the New COVID-19 Pill](#)

[Forbes.com](#)


[Molnupiravir: A New Hope for Prevention Treatment of Covid & Dangerous Viruses](#)

[Emory.edu](#)

[Molnupiravir and Drug Development at Emory](#)

Affordable Quality & Peace of Mind

The COVID Alliance Partners (GCAP) is a worldwide organization with a spirit of humanitarianism and sense of social responsibility. Working closely with government agencies, non-profits and manufactures, GCAP has created a quality, affordable molnupiravir.



GCAP takes quality seriously and ensures each box is manufactured to strict, high quality standards. To ensure you receive an authentic GCAP branded Molnupiravir, each box is printed with a anti-counterfeiting label. Using GCAP's mobile App, users can check the authenticity to ensure you've received a product you can be sure has meet GCAP's strict quality standards.



- This customized icon contains embedded covert technology to meet the highest security standards
- Scan this QR Code to receive drug information, production date and a detailed analysis report.